Treatment of infections, especially septicemia in hematological patients, with HBK

K. Toyama, Shinichiro Okamoto, H. Uchida, Y. Ando

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

HBK, a new aminoglycoside, was evaluated clinically for 19 infections of patients with hematological diseases. HBK was administered mainly by 1-hour intravenous drip infusion at a daily dose of 100~400 mg for 3 to 23 days. Daily dose and duration of HBK therapy were modified according to the patient's condition. After 1-hour intravenous drip infusion of 100 mg HBK, maximum blood concentrations were distributed from 4.42 μg/ml to 10.98 μg/ml. Two cases with septicemia, 6 possible septicemia and 4 other infections were treated with HBK alone, and 3 septicemia and 4 possible septicemia were treated with HBK combined with other chemotherapy. All 5 cases with septicemia responded to HBK alone or in combination chemotherapy. In 10 cases with possible septicemia, the clinical response to HBK alone and in combination therapy were observed in 4 and 1, respectively. The cases with other infections all responded to HBK alone. The overall response rate was 72%, so significant side effect was observed after the administration of HBK. From the above results, HBK was expected to be useful in the treatment of infection, especially septicemia, of hematological patients.

Original languageEnglish
Pages (from-to)193-198
Number of pages6
JournalChemotherapy
Volume34
Issue numberSUPPL. 1
Publication statusPublished - 1986

Fingerprint

Sepsis
Intravenous Infusions
Infection
Therapeutics
Hematologic Diseases
Aminoglycosides
Combination Drug Therapy
Drug Therapy

ASJC Scopus subject areas

  • Pharmacology

Cite this

Treatment of infections, especially septicemia in hematological patients, with HBK. / Toyama, K.; Okamoto, Shinichiro; Uchida, H.; Ando, Y.

In: Chemotherapy, Vol. 34, No. SUPPL. 1, 1986, p. 193-198.

Research output: Contribution to journalArticle

Toyama, K, Okamoto, S, Uchida, H & Ando, Y 1986, 'Treatment of infections, especially septicemia in hematological patients, with HBK', Chemotherapy, vol. 34, no. SUPPL. 1, pp. 193-198.
Toyama, K. ; Okamoto, Shinichiro ; Uchida, H. ; Ando, Y. / Treatment of infections, especially septicemia in hematological patients, with HBK. In: Chemotherapy. 1986 ; Vol. 34, No. SUPPL. 1. pp. 193-198.
@article{9113f3cdb42e4eda9f9c3715b897fae4,
title = "Treatment of infections, especially septicemia in hematological patients, with HBK",
abstract = "HBK, a new aminoglycoside, was evaluated clinically for 19 infections of patients with hematological diseases. HBK was administered mainly by 1-hour intravenous drip infusion at a daily dose of 100~400 mg for 3 to 23 days. Daily dose and duration of HBK therapy were modified according to the patient's condition. After 1-hour intravenous drip infusion of 100 mg HBK, maximum blood concentrations were distributed from 4.42 μg/ml to 10.98 μg/ml. Two cases with septicemia, 6 possible septicemia and 4 other infections were treated with HBK alone, and 3 septicemia and 4 possible septicemia were treated with HBK combined with other chemotherapy. All 5 cases with septicemia responded to HBK alone or in combination chemotherapy. In 10 cases with possible septicemia, the clinical response to HBK alone and in combination therapy were observed in 4 and 1, respectively. The cases with other infections all responded to HBK alone. The overall response rate was 72{\%}, so significant side effect was observed after the administration of HBK. From the above results, HBK was expected to be useful in the treatment of infection, especially septicemia, of hematological patients.",
author = "K. Toyama and Shinichiro Okamoto and H. Uchida and Y. Ando",
year = "1986",
language = "English",
volume = "34",
pages = "193--198",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Treatment of infections, especially septicemia in hematological patients, with HBK

AU - Toyama, K.

AU - Okamoto, Shinichiro

AU - Uchida, H.

AU - Ando, Y.

PY - 1986

Y1 - 1986

N2 - HBK, a new aminoglycoside, was evaluated clinically for 19 infections of patients with hematological diseases. HBK was administered mainly by 1-hour intravenous drip infusion at a daily dose of 100~400 mg for 3 to 23 days. Daily dose and duration of HBK therapy were modified according to the patient's condition. After 1-hour intravenous drip infusion of 100 mg HBK, maximum blood concentrations were distributed from 4.42 μg/ml to 10.98 μg/ml. Two cases with septicemia, 6 possible septicemia and 4 other infections were treated with HBK alone, and 3 septicemia and 4 possible septicemia were treated with HBK combined with other chemotherapy. All 5 cases with septicemia responded to HBK alone or in combination chemotherapy. In 10 cases with possible septicemia, the clinical response to HBK alone and in combination therapy were observed in 4 and 1, respectively. The cases with other infections all responded to HBK alone. The overall response rate was 72%, so significant side effect was observed after the administration of HBK. From the above results, HBK was expected to be useful in the treatment of infection, especially septicemia, of hematological patients.

AB - HBK, a new aminoglycoside, was evaluated clinically for 19 infections of patients with hematological diseases. HBK was administered mainly by 1-hour intravenous drip infusion at a daily dose of 100~400 mg for 3 to 23 days. Daily dose and duration of HBK therapy were modified according to the patient's condition. After 1-hour intravenous drip infusion of 100 mg HBK, maximum blood concentrations were distributed from 4.42 μg/ml to 10.98 μg/ml. Two cases with septicemia, 6 possible septicemia and 4 other infections were treated with HBK alone, and 3 septicemia and 4 possible septicemia were treated with HBK combined with other chemotherapy. All 5 cases with septicemia responded to HBK alone or in combination chemotherapy. In 10 cases with possible septicemia, the clinical response to HBK alone and in combination therapy were observed in 4 and 1, respectively. The cases with other infections all responded to HBK alone. The overall response rate was 72%, so significant side effect was observed after the administration of HBK. From the above results, HBK was expected to be useful in the treatment of infection, especially septicemia, of hematological patients.

UR - http://www.scopus.com/inward/record.url?scp=0022628365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022628365&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 193

EP - 198

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - SUPPL. 1

ER -